Celltrion Healthcare submitted a biologics license application (BLA) to the FDA for its biobetter of its infliximab biosimilar allowing for subcutaneous administration (Remsima SC).
Celltrion Healthcare announced its submission of a biologics license application (BLA) for Remsima SC, a biobetter of the company’s infliximab biosimilar (Remsima) that allows for subcutaneous administration.
Intravenous Remsima was approved by the FDA in April 2016 and launched on the US market in November 2016, where it is marketed as Inflectra through a commercialization agreement with Pfizer. It is 1 of 4 infliximab biosimilars approved in the United States.
Remsima SC can be offered in a prefilled syringe or auto-injector pen
Remsima SC (CT-P13) is the world first subcutaneous infliximab product, which can be a more convenient method of administration for patients than intravenous injection. Additionally, the biobetter has been shown to produce better clinical outcomes compared with the original Remsima, according to data presented at the European Congress of Rheumatology’s annual meeting in June 2022.
The data from the phase 3 study demonstrated the safety and efficacy profiles of Remsima SC as maintenance therapy in patients with moderate to severe active ulcerative colitis (LIBERTY-UC) and Crohn disease (LIBERTY-CD). The results showed that Remsima SC had superiority over placebo in maintenance therapy after induction therapy of intravenous formulation infliximab in patients with UC and CD, respectively, over 1 year. The studies featured 438 patients with UC and 343 patients with CD. Both studies were randomized, placebo controlled, and double blinded.
“This BLA submission marks a significant milestone for Celltrion and we are working with the FDA to bring this innovative treatment to the U.S. market…. We are committed to furthering the advancement of innovative treatments that provide improvements to clinical outcomes and drug pharmacology and reduce patients’ burden on their day-to-day lives,” said Hyoung Ki Kim, vice chairman and CEO of Celltrion Healthcare, in a statement.
Biobetters are a class of follow-on biologic products that are intentionally altered to improve clinical effects, allow for more time in between doses, or enhance tolerability. Although many biobetters are developed as alterations to originator biologics, Remsima SC is unique in that it is a biobetter based on a biosimilar of Remicade (reference infliximab).
According to Celltrion, using Remsima SC can offer patients better consistency in drug exposure and allow for better drug adherence compared with intravenous administration.
“We’re excited about the potential of CT-P13 SC as it allows patients to have more control of their treatment, providing much better independence and convenience…. In addition, CT-P13 SC releases the burden of having to travel to treatment for IV infusions, reducing treatment-related travel costs for patients and caregivers,” commented Jaeik Shim, chief operating officer at Celltrion USA.
In February 2021, Health Canada approved Remsima SC for the treatment of rheumatoid arthritis. The product is also approved in the Republic of Korea and the European Union.
In an interview with The Center for Biosimilars® in August 2022, Kim said that he anticipates the FDA’s approval decision during the second half of 2023.
“Biobetters could be transformative for the biopharmaceutical space going forward—in the same way that the introduction of biologic therapies and biosimilars were….In light of advancing technologies and innovative approaches, biobetters could allow for improved patient and health care professional choice, and ready-to-use formulations such as Remsima SC could reduce the handling burden for clinicians, especially in light of the [COVID-19] pandemic.”
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.